ATE135234T1 - Hemmung von arteriellem thrombotischen verschluss oder von thrombo-embolismus - Google Patents

Hemmung von arteriellem thrombotischen verschluss oder von thrombo-embolismus

Info

Publication number
ATE135234T1
ATE135234T1 AT88310800T AT88310800T ATE135234T1 AT E135234 T1 ATE135234 T1 AT E135234T1 AT 88310800 T AT88310800 T AT 88310800T AT 88310800 T AT88310800 T AT 88310800T AT E135234 T1 ATE135234 T1 AT E135234T1
Authority
AT
Austria
Prior art keywords
thrombo
embolism
inhibition
thrombotic occlusion
arterial thrombotic
Prior art date
Application number
AT88310800T
Other languages
English (en)
Inventor
John H Griffin
Andras Gruber
Stephen R Hanson
Lawrence A Harker
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22398288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE135234(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Application granted granted Critical
Publication of ATE135234T1 publication Critical patent/ATE135234T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT88310800T 1987-11-17 1988-11-16 Hemmung von arteriellem thrombotischen verschluss oder von thrombo-embolismus ATE135234T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/121,702 US5084274A (en) 1987-11-17 1987-11-17 Inhibition of arterial thrombotic occlusion or thromboembolism

Publications (1)

Publication Number Publication Date
ATE135234T1 true ATE135234T1 (de) 1996-03-15

Family

ID=22398288

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88310800T ATE135234T1 (de) 1987-11-17 1988-11-16 Hemmung von arteriellem thrombotischen verschluss oder von thrombo-embolismus

Country Status (11)

Country Link
US (2) US5084274A (de)
EP (1) EP0318201B1 (de)
JP (1) JP2766986B2 (de)
AT (1) ATE135234T1 (de)
CA (1) CA1330036C (de)
DE (1) DE3855096T2 (de)
DK (1) DK175704B1 (de)
ES (1) ES2086301T3 (de)
FI (1) FI104790B (de)
GR (1) GR3020036T3 (de)
NO (1) NO301747B1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
JP2739050B2 (ja) 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
AU7168591A (en) * 1989-12-29 1991-07-24 Zymogenetics Inc. Hybrid protein c
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
FR2671973A1 (fr) * 1991-01-25 1992-07-31 Fondation Nale Transfusion San Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
CA2107476C (en) * 1991-04-16 2007-12-18 Martin Ulrich Pharmaceutical packaging unit containing plasminogen activators for multiple bolus administration
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
AT395596B (de) * 1991-06-20 1993-01-25 Immuno Ag Verfahren zur herstellung von aktiviertem protein c
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
AT402263B (de) * 1991-06-20 1997-03-25 Immuno Ag Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
WO1993009807A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
JPH05271098A (ja) * 1992-03-26 1993-10-19 Teijin Ltd 活性化プロテインｃを有効成分とする抗血小板剤
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
US6143719A (en) * 1995-06-09 2000-11-07 The Regents Of The University Of Michigan Bradykinin analogs as selective thrombin inhibitors
WO1998042358A1 (en) * 1997-03-24 1998-10-01 Eli Lilly And Company Methods for treating vascular disorders
US6982249B1 (en) 1997-04-23 2006-01-03 The Regents Of The University Of Michigan Bradykinin analogs as selective inhibitors of cell activation
CA2293429A1 (en) * 1997-06-05 1998-12-10 Eli Lilly And Company Methods for treating thrombotic disorders
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
IL142247A0 (en) 1998-11-23 2002-03-10 Lilly Co Eli Method of treating sickle cell disease and thalassemia
WO2001056532A2 (en) * 2000-02-04 2001-08-09 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US7087578B2 (en) 2000-05-24 2006-08-08 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
AU2003265898A1 (en) * 2002-09-05 2004-03-29 Genentech, Inc. Infusion catheter having an integrated doppler transducer
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
EP1651252B1 (de) * 2003-07-08 2014-11-26 The Scripps Research Institute Aktivierte protein c varianten mit normaler zytoprotektiver aktivität aber verringerter gerinnungshemmender aktivität
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
UA95903C2 (ru) 2005-02-24 2011-09-26 Дифьюжен Фармасьютикалз Ллк Транс-каротиноиды, их синтез, лекарственная форма и применение
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
EP2078074A4 (de) * 2006-10-31 2011-09-28 Scripps Research Inst Dosierplan für aktiviertes protein-c und varianten mit verminderter gerinnungshemmender wirkung
EP3483140A1 (de) 2007-04-13 2019-05-15 Diffusion Pharmaceuticals LLC Verwendung von bipolaren trans-karotinoiden als eine vorbehandlung und bei der behandlung von peripherer gefässkrankheit
KR101875843B1 (ko) 2009-06-22 2018-07-06 디퓨젼 파마슈티컬즈 엘엘씨 확산 촉진 화합물 및 그 화합물 단독 또는 혈전 용해제와 합쳐진 화합물의 용도
CN105287473A (zh) 2010-06-02 2016-02-03 扩散药品有限公司 包含双极性反式类胡萝卜素的组合物及其应用
JP6273272B2 (ja) 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
ES2890623T3 (es) 2014-04-16 2022-01-20 Zz Biotech Llc Uso del análogo de APC para curar heridas
DK3137102T3 (da) 2014-04-16 2021-10-11 Zz Biotech Llc Apc til anvendelse til behandling af unormal kutan ardannelse
WO2017165667A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
JPS6011427A (ja) * 1983-06-29 1985-01-21 Green Cross Corp:The 血栓溶解性蛋白の疾患局所親和性向上方法
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds
EP0156169B1 (de) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha Wässrige Lösung eines darin in erhöhter Konzentration aufgelösten Gewebe-Plasminogen-Aktivators und Herstellungsverfahren
AU595173B2 (en) * 1985-01-08 1990-03-29 General Hospital Corporation, The Method and use for site-specific activation of substances
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
DE3688900T3 (de) * 1985-06-27 1998-06-10 Univ Washington Expression von Protein C.
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4929602A (en) * 1987-11-25 1990-05-29 Scripps Clinic And Research Foundation Method of inhibiting platelet dependent arterial thrombosis

Also Published As

Publication number Publication date
EP0318201A2 (de) 1989-05-31
NO301747B1 (no) 1997-12-08
FI104790B (fi) 2000-04-14
DE3855096T2 (de) 1996-07-25
JPH01238536A (ja) 1989-09-22
FI885331A0 (fi) 1988-11-17
ES2086301T3 (es) 1996-07-01
US5084274A (en) 1992-01-28
US5350578A (en) 1994-09-27
JP2766986B2 (ja) 1998-06-18
DK640088D0 (da) 1988-11-16
CA1330036C (en) 1994-06-07
EP0318201B1 (de) 1996-03-13
DK640088A (da) 1989-05-18
DE3855096D1 (de) 1996-04-18
EP0318201A3 (en) 1990-02-07
GR3020036T3 (en) 1996-08-31
DK175704B1 (da) 2005-01-24
NO885109L (no) 1989-05-18
FI885331L (fi) 1989-05-18
NO885109D0 (no) 1988-11-16

Similar Documents

Publication Publication Date Title
DE3855096D1 (de) Hemmung von arteriellem thrombotischen Verschluss oder von Thrombo-Embolismus
DK463989D0 (da) Farmaceutisk virksom kombination
AU657758B2 (en) A parenterally administrable drug having thrombolytic activity and containing protein C
DE3874798D1 (de) Therapeutisches proteinagens in form von aerosol.
ATE120206T1 (de) Peptide, die die bindung des von-willebrand- faktors inhibieren.
DE3880480D1 (de) Hemolyse-inhibitor und plastifizierungsmittel.
ATE104151T1 (de) Trombosebehandlung mit fibrinolytika und prostacyclinen.
DE69110713D1 (de) 7-Oxabicycloheptan-imidazol-prostaglandin-Analoge, verwendbar bei der Behandlung von thrombotischen und vasospastischen Erkrankungen.
DK627687A (da) Hirudinvariant
DK50987A (da) Polypeptid med plasminogenaktivatorvirkning
FI883943A7 (fi) Muunnetut plasminogeeni aktivaattorit.
DE69023459D1 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
DK213589A (da) Antistoffer mod fibrin og immunogen til brug ved fremstilling deraf
DK301589A (da) Laegemiddel med thrombolytisk virkning
DK0458537T3 (da) Anvendelse af en terapeutisk forbindelse til behandling af bronkitis
MX174250B (es) Composicion con actividad antiagregante de plaqueta util en terapias
DK37988A (da) Fibrinolytisk vaevstype-plasminogenaktivator
EP0191814A4 (de) Absorptionsverbesserer für proteine.

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee